Enhancing Function Using the RF Microstimulator Gait System Following Stroke 2008
- Conditions
- Stroke
- Interventions
- Device: radio frequency-controlled (RF) Microstimulator (RFM) Gait System
- Registration Number
- NCT00864708
- Lead Sponsor
- US Department of Veterans Affairs
- Brief Summary
The purpose of the study is to investigate new Technology for recovery of ankle walking function after stroke.
- Detailed Description
Background and Purpose: Conventional rehabilitation does not restore normal, upper limb function or normal gait to many stroke survivors. Functional neuromuscular stimulation (FNS) has shown promise for functional enhancement of both upper and lower limb motor control following stroke. Gains included muscle activation latencies, strength, coordination, upper limb functional tasks, gait kinematics, walking endurance, and quality of life. The purpose of the proposed work is to test the radio frequency-controlled (RF) Microstimulator (RFM) Gait System regarding system performance and subject response to treatment.
Methods: This is a feasibility study in which up to four subjects will receive the (RFM) Gait System. Up to ten RFMs will be placed for a given subject. An RFM ankle muscle system will be used to train ankle gait components. A separate RFM system will be used to train knee gait components. Subjects will be treated for 6 months, four sessions/wk. Primary outcome measures for the RFM Gait System will be: kinematic swing phase gait components and walking endurance. Secondary outcome measures will include: strength, coordination, spasticity, function, and quality of life. Data collections will occur at months 1, 3 and 6, and for follow-up times up to a year after the end of treatment. The results of the RFM ankle system have the potential to provide a new technology for ankle muscle gait components.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 1
- Sufficient endurance to participate in rehabilitation sessions.
- Medically Stable
- Age >21 years.
- Inability to perform normal ankle coordinated gait components.
- Participants should be able to walk and keep balance without physical assistance from another person
- Acute or progressive cardiac, renal, respiratory, neurological disorders or malignancy.
- Lower motor neuron damage or radiculopathy
- Allergy or contraindication to anesthesia, Versed, (or comparable substitute.
- Active implantable device (e.g. pacemaker, implantable cardiac defibrillator, neurostimulator, or drug infusion device.
- Pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Arm 1 radio frequency-controlled (RF) Microstimulator (RFM) Gait System radio frequency-controlled (RF) Microstimulator (RFM) Gait System
- Primary Outcome Measures
Name Time Method Walking Endurance (6MWT) Day 1 and at 3 months, following treatment The Six Minute Walk Test (6MWT) is a measure of the distance measured in feet ambulated by the participant during six minutes. A further distance walked in 6 minutes indicates improvement on the measure.
Kinematic Gait Measures Day 1 and at 3 months, following treatment assessment of the lower limb kinematics during ambulation at chosen speed.
- Secondary Outcome Measures
Name Time Method Fugl-Meyer Lower Extremity Score Day 1 and at 3 months, following treatment Fugl-Meyer Lower Extremity Score (FMLE) is an itemized measure of lower extremity coordination following stroke. Scores for the FMLE range from 0 (most impaired) to 34 (normal).
Ashworth Scale Day 1 and at 3 months, following treatment The Ashworth Scale is a measure of muscle spasticity; muscle groups are graded from 0 (no spasticity) to 4 (greatest spasticity/contracture). The lower limb muscle groups are summed for a total lower limb Ashworth score. A lower score indicates better performance. (range is 0-40)
Stroke Impact Scale (SIS) Day 1 and at 3 months, following treatment The SIS is a measure of Quality of Life/Life Role Participation following stroke. Each item in a domain is scored between 0 and 5. A higher score indicates better performance (range 0-295).
Manual Muscle Testing (MMT) Day 1 and at 3 months, following treatment This is a measure of strength of the various muscle groups of the lower limb. Each is graded on a 0 to 5 scale; the final score is the summed total of the lower limb muscle groups tested. (score range of summed muscles is 0-50, with 50 being the maximum highest score)
Trial Locations
- Locations (1)
VA Medical Center, Cleveland
🇺🇸Cleveland, Ohio, United States